DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/7xvlgl/cushioning_the) has announced the addition of the "Cushioning the Patent Impact and Preparing for Growth: Analysis of Big Pharma's Diversification Strategy to Overcome Industry Challenges" report to their offering.
Diversification is a key strategy for pharmaceutical companies to overcome the challenges facing the industry, such as the genericization of key brand drugs, a challenging payer environment and declining research and development (R&D) productivity. By diversifying into markets, such as the emerging markets, consumer and animal healthcare and vaccines, companies hope to grow their portfolios, but they also reduce the contribution from key brands that will become generalized in the future. Diversification may also potentially reduce the overall corporate risk by exposing a portfolio to different risk factors, such as the susceptibility of economic cycles, target customers, geographical markets and R&D risk. While many leading companies are now looking to diversify their portfolios, each company has a mixture of activities as part of its diversification strategy.
In this report we explore how a diversification strategy overcomes the industry's challenges, the key developments in companies pursuing a diversification strategy and how companies are diversifying their portfolios.
The report focuses on AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche and Sanofi Aventis although there is discussion on other companies where appropriate.
- The pharma industry is facing multiple challenges including the onset of the patent cliff, stagnant R&D productivity and a challenging payer environment. How does a diversification strategy overcome the industry's headwinds?
- Leading pharma companies are employing different strategies to overcome the industry's challenges. For instance, some companies are focusing on biopharmaceuticals whereas others are increasing their exposure to consumer healthcare. How are the leading pharma companies employing different strategies? What is the rationale for the different strategies by leading companies?
- The industry has seen several large-scale mergers and acquisitions including Pfizer's of Wyeth and Merck with Schering Plough in 2009. How have these mergers and acquisitions minimized the impact of the industry's challenges? Which companies have had the largest increase in the level of diversification of their pharmaceutical portfolio?
- Companies are diversifying their pharmaceutical portfolio outside of the U.S.-market. What is the rationale for companies to reduce their exposure outside of U.S.-pharmaceuticals? Which companies have been the most active in diversifying their pharmaceutical portfolio outside of the U.S.-market?
Key Topics Covered:
1. The Challenges
2. The Opportunities
3. Growth Enabling Strategies
4. Diversification Strategy Analysis
5. Company Portfolio Analysis
6. Company Diversification Strategy
7. R&D And Other Initiatives
Companies Mentioned - Please click here for a list of companies mentioned:
- Bristol-Myers Squibb
- Eli Lilly and Company
- FoldRx Pharmaceuticals
- Johnson & Johnson
- Novo Nordisk
- Sanofi Aventis
- Sun Pharmaceutical Industries
For more information visit http://www.researchandmarkets.com/research/7xvlgl/cushioning_the